Stock Surge: Aditxt Inc. (NASDAQ: ADTX) shares rose 52.11% to $2.16 in after-hours trading following the announcement of a special stockholder meeting scheduled for January 30, 2026.
Shareholder Proposals: The proxy statement includes several proposals for shareholder approval, including compliance with Nasdaq rules for stock issuances, an Employee Stock Purchase Plan, and an amendment to the Omnibus Equity Incentive Plan.
Reverse Stock Split and Name Change: The board seeks approval for a potential reverse stock split and a non-binding advisory vote on changing the company name to "bitXbio, Inc."
Trading Performance: Despite the recent surge, ADTX has experienced a 99.97% decline year-to-date, with a current market capitalization of approximately $794,410.
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
